| Literature DB >> 29326192 |
Molly Rosenberg1, Audrey Pettifor2,3,4, Rhian Twine4, James P Hughes5, F Xavier Gomez-Olive4,6,7, Ryan G Wagner4,8, Afolabi Sulaimon4, Stephen Tollman4,7,8, Amanda Selin3, Catherine MacPhail4,9,10, Kathleen Kahn4,7,8.
Abstract
OBJECTIVES: We examined the potential influence of both sample selection effects and Hawthorne effects in the behavioural HIV Prevention Trial Network 068 study, designed to examine whether cash transfers conditional on school attendance reduce HIV acquisition in young South African women. We explored whether school enrolment among study participants differed from the underlying population, and whether differences existed at baseline (sample selection effect) or arose during study participation (Hawthorne effect).Entities:
Keywords: HIV prevention; Hawthorne effect; South Africa; adolescents; selection effect
Mesh:
Year: 2018 PMID: 29326192 PMCID: PMC5781067 DOI: 10.1136/bmjopen-2017-019167
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Timeline of Agincourt HDSS education data collection and HPTN 068 trial duration. HDSS, Health and socio-Demographic Surveillance System; HPTN, HIV Prevention Trial Network.
Sociodemographic characteristics of a cohort of 3889 young women between the ages of 11 and 20 years in rural Agincourt, South Africa, by participation in the HPTN 068 trial
| Total (n=3889) | Trial participant | Non-participant (n=2169) | P value | ||||
| n | % | n | % | n | % | ||
| Age in 2011 | <0.0001 | ||||||
| 11–12 | 188 | 4.8 | 26 | 1.5 | 162 | 7.5 | |
| 13–14 | 1270 | 32.7 | 637 | 37.0 | 633 | 29.2 | |
| 15–16 | 1591 | 40.9 | 793 | 46.1 | 798 | 36.8 | |
| 17–18 | 667 | 17.2 | 239 | 13.9 | 428 | 19.7 | |
| 19–20 | 173 | 4.5 | 25 | 1.5 | 148 | 6.8 | |
| SES | 0.003 | ||||||
| At or above median | 1778 | 50 | 853 | 52.7 | 925 | 47.8 | |
| Below median | 1778 | 50 | 766 | 47.3 | 1012 | 52.3 | |
| Missing | 333 | 101 | 232 | ||||
| Household size | 0.5 | ||||||
| Mean | 8.4 | 8.4 | 8.5 | ||||
| SD | 4.2 | 4.0 | 4.4 | ||||
| Missing | 46 | 14 | 32 | ||||
| Gender of household head | 0.3 | ||||||
| Female | 1590 | 41.7 | 691 | 40.8 | 899 | 42.4 | |
| Male | 2224 | 58.3 | 1004 | 59.2 | 1220 | 57.6 | |
| Missing | 75 | 25 | 50 | ||||
| Household head educational attainment | 0.02 | ||||||
| <Grade 12 | 3062 | 86.3 | 1398 | 87.8 | 1664 | 85.1 | |
| Grade 12 or higher | 486 | 13.7 | 194 | 12.2 | 292 | 14.9 | |
| Missing | 341 | 128 | 213 | ||||
| Country of origin | 0.2 | ||||||
| South Africa | 2315 | 59.6 | 1046 | 60.9 | 1269 | 58.6 | |
| Mozambique | 1570 | 40.4 | 673 | 39.2 | 897 | 41.4 | |
| Missing | 4 | 1 | 3 | ||||
| Childbearing before 2011 | <0.0001 | ||||||
| Yes | 274 | 7.1 | 67 | 3.9 | 207 | 9.5 | |
| No | 3615 | 93.0 | 1653 | 96.1 | 1962 | 90.5 | |
| Intervention arm | |||||||
| Control | 820 | 50.4 | |||||
| Intervention | 806 | 49.6 | |||||
| 2011 school enrolment | <0.0001 | ||||||
| Yes | 3508 | 95.7 | 1637 | 99.2 | 1871 | 92.9 | |
| No | 158 | 4.3 | 14 | 0.9 | 144 | 7.2 | |
| Missing | 223 | 69 | 154 | ||||
| 2015 school enrolment | <0.0001 | ||||||
| Yes | 2465 | 74.2 | 1234 | 19 | 1231 | 68.5 | |
| No | 856 | 25.8 | 290 | 81 | 566 | 31.5 | |
| Missing | 568 | 196 | 372 | ||||
*Due to restrictions in the cohort construction to maintain comparable groups with respect to age and education status in 2009, not all of the 2533 HPTN 068 participants are represented.
†P values for categorical variables are from Χ2 tests and for continuous variables from t-tests.
‡Measured in 2009.
HPTN, HIV Prevention Trial Network; SES, socioeconomic status.
The relationship between HPTN 068 trial participation and school enrolment in 2011 and 2015, stratified by age, in the full cohort and the cohort restricted to those enrolled in school in 2011
| Enrolment | n | Per cent enrolled | RD (95% CI) | aRD | |
| 2011: full cohort | |||||
| All ages | |||||
| Trial participant | 1637 | 1651 | 99.2 (98.7, 99.6) | 6.3 (5.1 to 7.5) | 2.9 (−0.7 to 6.5) |
| Non-trial participant | 1871 | 2015 | 92.9 (91.7, 94.0) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant | 1036 | 1038 | 99.8 (99.5, 1.00) | 0.6 (0.0 to 1.2) | 0.4 (−5.2 to 5.9) |
| Non-trial participant | 1115 | 1124 | 99.2 (98.6, 99.7) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant | 532 | 539 | 98.7 (97.8, 99.7) | 6.9 (4.6 to 9.2) | 6.3 (0.5 to 12.2) |
| Non-trial participant | 593 | 646 | 91.8 (89.7, 93.9) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant | 69 | 74 | 93.2 (87.5, 99.0) | 26.7 (18.5 to 34.9) | 19.5 (5.6 to 33.3) |
| Non-trial participant | 163 | 245 | 66.5 (60.6, 72.4) | 1 | 1 |
| 2015: full cohort | |||||
| All ages | |||||
| Trial participant | 1234 | 1524 | 81.0 (79.0, 83.0) | 12.5 (9.6 to 15.4) | 6.8 (3.4 to 10.2) |
| Non-trial participant | 1231 | 1797 | 68.5 (66.4, 70.7) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant | 837 | 952 | 87.9 (85.9, 90.0) | 3.8 (0.1 to 6.9) | 1.9 (− 1.3 to 5.0) |
| Non-trial participant | 833 | 990 | 84.1 (81.9, 86.5) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant | 361 | 503 | 71.8 (67.9, 75.8) | 12.5 (6.9 to 18.1) | 12.7 (6.7 to 18.7) |
| Non-trial participant | 346 | 584 | 59.3 (55.4, 63.4) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant | 36 | 69 | 52.2 (41.6, 65.4) | 28.9 (15.8 to 41.9) | 29.7 (16.1 to 43.3) |
| Non-trial participant | 52 | 223 | 23.3 (18.4, 29.6) | 1 | 1 |
| 2015: restricted cohort | |||||
| All ages | |||||
| Trial participant | 1234 | 1510 | 81.7 (79.8, 83.7) | 7.3 (4.5 to 10.2) | 4.9 (1.5 to 8.3) |
| Non-trial participant | 1231 | 1655 | 74.4 (72.3, 76.5) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant | 837 | 950 | 88.1 (86.1, 90.2) | 3.2 (0.2 to 6.3) | 1.8 (−1.3 to 5.0) |
| Non-trial participant | 833 | 982 | 84.8 (82.6, 87.1) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant | 361 | 496 | 72.8 (69.0, 76.8) | 7.6 (1.9 to 13.3) | 7.9 (1.9 to 14.0) |
| Non-trial participant | 346 | 531 | 65.2 (61.2, 69.3) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant | 36 | 64 | 56.3 (45.3, 69.8) | 19.6 (5.1 to 34.1) | 22.8 (7.3 to 38.2) |
| Non-trial participant | 52 | 142 | 36.6 (29.5, 45.5) | 1 | 1 |
*Adjusted for socioeconomic status (coded dichotomously at median household asset index score), country of origin (South African vs Mozambican), educational attainment of household head (coded dichotomously at grade 12 attainment), gender of household head (male vs female), household size (coded linearly) and pre-2011 childbearing (yes vs no). Models that are not age-stratified are also adjusted for age coded in 2-year categories.
†Restricted to all young women who were enrolled in school in 2011.
aRD, adjusted risk difference; HPTN, HIV Prevention Trial Network; RD, risk difference.
Sensitivity analysis comparing differences in school enrolment between HPTN 068 trial participants in the control arm only and non-trial participants
| Enrolment | n | Per cent enrolled | RD (95% CI) | aRD* (95% CI) | |
| 2011: full cohort | |||||
| All ages | |||||
| Trial participant (control) | 862 | 872 | 98.9 (98.2, 99.6) | 6.0 (4.7 to 7.3) | 3.2 (−1.4 to 7.7) |
| Non-trial participant | 1871 | 2015 | 92.9 (91.7, 94.0) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant (control) | 543 | 544 | 99.8 (99.5, 1.00) | 0.6 (0.0 to 1.3) | 0.4 (−7.3 to 8.0) |
| Non-trial participant | 1115 | 1124 | 99.2 (98.6, 99.7 | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant (control) | 280 | 285 | 98.3 (96.7, 99.8) | 6.5 (3.8 to 9.1) | 5.7 (−0.9 to 12.3) |
| Non-trial participant | 593 | 646 | 91.8 (89.7, 93.9) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant (control) | 39 | 43 | 90.7 (82.0, 99.4) | 24.2 (13.7 to 34.7) | 17.7 (2.6 to 32.8) |
| Non-trial participant | 163 | 245 | 66.5 (60.6, 72.4) | 1 | 1 |
| 2015: full cohort | |||||
| All ages | |||||
| Trial participant (control) | 653 | 813 | 80.3 (77.6, 83.1) | 11.8 (8.3 to 15.3) | 6.9 (3.6 to 10.3) |
| Non-trial participant | 1231 | 1797 | 68.5 (66.4, 70.7) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant (control) | 448 | 504 | 88.9 (86.2, 91.6) | 4.8 (1.2 to 8.3) | 2.4 (−1.3 to 6.1) |
| Non-trial participant | 833 | 990 | 84.1 (81.9, 86.5) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant (control) | 186 | 269 | 69.1 (63.6, 74.7) | 9.9 (3.1 to 16.7) | 9.7 (2.6 to 16.8) |
| Non-trial participant | 346 | 584 | 59.3 (55.4, 63.4) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant (control) | 19 | 40 | 47.5 (32.0, 63.0) | 24.2 (7.7 to 40.6) | 21.5 (4.9 to 38.1) |
| Non-trial participant | 52 | 223 | 23.3 (18.4, 29.6) | 1 | 1 |
| 2015: restricted cohort | |||||
| All ages | |||||
| Trial participant (control) | 653 | 803 | 81.3 (78.6, 84.0) | 6.9 (3.5 to 10.4) | 4.5 (1.3 to 7.6) |
| Non-trial participant | 1231 | 1655 | 74.4 (72.3, 76.5) | 1 | 1 |
| Ages 11–15 | |||||
| Trial participant (control) | 448 | 503 | 89.1 (86.3, 91.8) | 4.2 (0.7 to 7.8) | 2.5 (−1.2 to 6.2) |
| Non-trial participant | 833 | 982 | 84.8 (82.6, 87.1) | 1 | 1 |
| Ages 16–17 | |||||
| Trial participant (control) | 186 | 264 | 70.5 (65.0, 76.0) | 5.3 (−1.5 to 12.1) | 5.2 (−2.0 to 12.3) |
| Non-trial participant | 346 | 531 | 65.2 (61.2, 69.3) | 1 | 1 |
| Ages 18–20 | |||||
| Trial participant (control) | 19 | 36 | 52.8 (36.5, 69.1) | 16.2 (−2.0 to 34.3) | 13.8 (−5.7 to 33.4) |
| Non-trial participant | 52 | 142 | 36.6 (29.5, 45.5) | 1 | 1 |
School enrolment outcome was analysed in 2011 and 2015 and the analysis was stratified by age, in the full cohort and the cohort restricted to those enrolled in school in 2011.
*Adjusted for socioeconomic status (coded dichotomously at median household asset index score), country of origin (South African vs Mozambican), educational attainment of household head (coded dichotomously at grade 12 attainment), gender of household head (male vs female), household size (coded linearly) and pre-2011 childbearing (yes vs no). Models that are not age-stratified are also adjusted for age coded in 2-year categories.
†Restricted to all young women who were enrolled in school in 2011.
aRD, adjusted risk difference; HPTN, HIV Prevention Trial Network; RD, risk difference.